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Abstract
Aging is associated with a reduction in osteoblast life span and the volume of
bone formed by each basic multicellular unit. Each time bone is resorbed, less
is deposited producing microstructural deterioration. Aging is also associated
with insulin resistance and hyperglycemia, either of which may cause, or be
the result of, a decline in undercarboxylated osteocalcin (ucOC), a protein
produced by osteoblasts that increases insulin sensitivity. We examined
whether glucose-loading reduces bone remodeling and ucOC in vivo and
osteoblast function in vitro, and so compromises bone formation. We admin-
istered an oral glucose tolerance test (OGTT) to 18 pre and postmenopausal,
nondiabetic women at rest and following exercise and measured serum levels
of bone remodeling markers (BRMs) and ucOC. We also assessed whether
increasing glucose concentrations with or without insulin reduced survival
and activity of cultured human osteoblasts. Glucose-loading at rest and fol-
lowing exercise reduced BRMs in pre and postmenopausal women and
reduced ucOC in postmenopausal women. Higher glucose correlated nega-
tively, whereas insulin correlated positively, with baseline BRMs and ucOC.
The increase in serum glucose following resting OGTT was associated with
the reduction in bone formation markers. D-glucose (>10 mmol L1)
increased osteoblast apoptosis, reduced cell activity and osteocalcin expression
compared with 5 mmol L1. Insulin had a protective effect on these parame-
ters. Collagen expression in vitro was not affected in this time course. In con-
clusion, glucose exposure reduces BRMs in women and exercise failed to
attenuate this suppression effect. The suppressive effect of glucose on BRMs
may be due to impaired osteoblast work and longevity. Whether glucose influ-
ences material composition and microstructure remains to be determined.
Introduction
Skeletal health is maintained throughout life by the cellu-
lar machinery of bone remodeling, the final common
pathway mediating the effects of all genetic and environ-
mental factors on the material composition, microstruc-
ture, and strength of bone (Parfitt 2008). Around midlife
bone remodeling becomes unbalanced as the volume of
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bone formed by each basic multicellular unit (BMU) is
less than was resorbed (Lips et al. 1978). Each time bone
is remodeled, a small volume of bone is lost, structural
deterioration follows and increases bone fragility.
Thus, the age-related reduction in the volume of bone
formed by each BMU plays a central role in the patho-
genesis of bone fragility. Aging is also associated with
insulin resistance. The insulin resistance and any existing
hyperglycemia may each reduce the volume of bone
formed by osteoblasts of the BMU and reduce the rate of
bone remodeling. For example, bone remodeling markers
(BRMs) are suppressed after a meal or following a glu-
cose-load in healthy women and in women with insulin
resistance (Clowes et al. 2002; Schwetz et al. 2014). In
obese subjects, higher serum glucose is associated with
lower levels of BRMs (Iglesias et al. 2011).
The suppressive effect of a glucose-load is likely to be
related to the high circulating glucose levels and not the
accompanying higher insulin levels as insulin is anabolic
and is capable of promoting osteoblastic proliferation and
differentiation as well as inducing increased markers of
bone formation like alkaline phosphatase (ALP) and
osteocalcin (OC) (Yang et al. 2010). Although the reduc-
tion in bone formation produced by hyperglycemia may
produce structural decay, any slowing of remodeling pro-
duced by hyperglycemia may attenuate bone loss and
structural deterioration accounting for the finding of nor-
mal or high bone mineral density (BMD) in women with
diabetes. However, the slowing of remodeling may com-
promise bone’s ‘qualities’; the brittleness of the unremod-
eled bone matrix is increased by increasing collagen
cross-linking and increasing the completeness of tissue
mineralization which may explain the increased fracture
risk in women with type 2 diabetes despite normal or
higher BMD (Schwartz et al. 2011; Leslie et al. 2012).
Undercarboxylated osteocalcin (ucOC) participates in
glucose homeostasis in mice and humans (Lee et al. 2007;
Iglesias et al. 2011; Levinger et al. 2011; Brennan-Sper-
anza et al. 2012; Schwetz et al. 2014). Osteocalcin (OC), a
protein synthesized exclusively by osteoblasts, undergoes
posttranslational carboxylation but not all of the OC is
carboxylated; some remains undercarboxylated(Pittas
et al. 2009) and this osteoblast product contributes to the
regulation of insulin secretion and sensitivity in both
mice and human subjects (Lee et al. 2007; Ferron et al.
2008, 2012; Iglesias et al. 2011; Levinger et al. 2011; Bren-
nan-Speranza et al. 2012; Schwetz et al. 2014).
Obese subjects and patients with type 2 diabetes have
reduced circulating ucOC, which compromises insulin
sensitivity resulting in higher glucose levels (Fernandez-
Real et al. 2009; Kanazawa et al. 2009, 2011; Brennan-
Speranza and Conigrave 2015). However, it is plausible
that this is bidirectional; low ucOC cause high glucose,
and high glucose reduces ucOC (Paldanius et al. 2012).
Exercise does the reverse – it increases insulin sensitivity
by improving muscle glucose uptake and, partly, by
increasing ucOC (Levinger et al. 2011, 2014). OC, ucOC
and b-isomerized C-terminal telopeptides (b-CTX)
increase after acute exercise (Guillemant et al. 2004; Scott
et al. 2010; Levinger et al. 2011, 2014). Whether exercise
prevents the suppressive effect of a glucose-load on BRMs
in women is not clear.
Thus, prospective studies are needed to determine
whether a glucose-load reduces circulating ucOC levels in
women. Moreover, as BRMs are affected by many con-
founders in vivo, in vitro studies are needed to identify
the direct role of glucose and insulin on osteoblasts. We
hypothesized that (1) at rest, a glucose-load will suppress
BRMs, and (2), that exercise prior to glucose-load
increases BRMs thereby attenuating the suppressive effect
of the glucose-load, (3) that there will be direct effects of
glucose and insulin on cultured primary human osteo-
blast survival and function in vitro; high glucose will
stimulate apoptosis and reduce osteoblast viability and
ALP activity, and expression of the bone formation mark-
ers osteocalcin and type 1 collagen. Furthermore, we
hypothesized that insulin treatment will prevent the nega-
tive effects of high glucose on osteoblasts in vitro.
Materials and Methods
In vivo study
Participants
Premenopausal women (n = 8, age = 36.1  2.7 years,
BMI = 25.5  0.8) were eligible for the study if they were
between 20 and 50 years of age and had regular men-
strual cycles (Table 1). Postmenopausal women (n = 10,
age = 62.8  2.6 years, BMI = 28.3  1.3 kg m2) were
eligible if they experienced >12 months of amenorrhea as
a result of a natural menopause. Women who were
perimenopausal, with musculoskeletal or other conditions
that prevented daily activity and symptomatic or
uncontrolled metabolic or cardiovascular disease and
those taking warfarin or vitamin K supplementation, anti-
hyperglycemic medications were excluded. Each partici-
pant was given written and verbal explanations about the
study before signing an informed consent form. The study
protocol was approved by the Human Research Ethics
Committee, Victoria University.
Study protocol
The study was a randomized-control, crossover design.
Participants underwent an initial assessment including
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anthropometric measurements, assessment of peak aerobic
power (VO2peak) and a fasting blood test. Following the
completion of the baseline assessments, participants were
randomly assigned to two sessions of an oral glucose tol-
erance test (OGTT) following rest (control trial) and fol-
lowing an acute bout of aerobic exercise. The two
sessions were performed approximately 1 week apart.
Weight was measured using a calibrated scale
(TANITA, Tanita Corporation, Tokyo, Japan). Height
was measured with an electronic stadiometer (Proscale,
Accurate Technology Inc., Fletcher, NC). Participants
were required to wear a 12-lead electrocardiogram
(ECG; Mortara, X-Scribe II, Milwaukee, WI) during a
symptom-limited graded exercise test, performed on a
Cybex MET 100 cycle ergometer (Cybex Metabolic Sys-
tems, Ronkinkoma, NY) as described previously (Levin-
ger et al. 2007, 2014). The graded exercise test was
terminated when a rating of perceived exertion of ‘very
hard’ (Borg scale = 17) was achieved. VO2 for each 15-s
interval was measured by gas analysis (Medgraphics,
Cardio2 and CPX/D System with Breezeex Software,
142090-001, Revia, MN), which was calibrated before
each test. A blood sample was collected following an
overnight fast. Blood was analyzed at Austin Health
pathology (Melbourne, Australia) using standard hospital
assay protocols for glucose, HbA1c and insulin.
Participants performed a standard 75 g of OGTT fol-
lowing an overnight fast. Venous blood samples were col-
lected at baseline and 120 min after the glucose load,
centrifuged and immediately stored at 80°C. Serum was
analyzed for glucose, insulin, and BRMs. In the second
trial, acute aerobic exercise was performed on a cycle
ergometer for 30 min at an intensity corresponding to
70–75% of VO2peak. The exercise intensity was adjusted
every 5 min to maintain a heart rate range in the desired
intensity. Participants recovered for 60 min before under-
taking a standard 75 g OGTT.
Blood samples were obtained immediately postexercise
and at 30 and 60 min post exercise and 120 min after the
glucose load. Total serum OC was measured using an
automated immunoassay (Elecsys 170; Roche Diagnos-
tics). This assay has a sensitivity of 0.5 lg L1, with an
intra-assay precision of 1.3%. Serum ucOC was measured
by the same immunoassay after adsorption of carboxy-
lated OC on 5 mg/mL hydroxyl-apatite slurry, following
the method described by Gundberg et al. (1998). The
ucOC values on these samples of 6.0–35.6 lg L1 and %
unbound osteocalcin between 38.1 and 51.4% are in
keeping with the original assay validation. The interassay
CV for total OC is 8.3% and the interassay CV for ucOC
is 5.7%. tOC and ucOC assays were performed at Path-
West QEII Medical Centre, Perth. Insulin, b-isomerized
C-terminal telopeptides (b-CTx, a bone resorption mar-
ker) and procollagen 1 N-terminal propeptide (P1NP, a
bone formation marker) were analyzed at Austin pathol-
ogy, Melbourne using a Roche Hitachi Cobas e602
immunoassay analyzer, according to the manufacturer’s
guidelines.
In vitro study: assays of cultured human
osteoblasts (HOBs)
Cell culture
Primary human osteoblasts (HOBs) were grown from the
minced trabecular ends of fetal long bone in accordance
with the National Health and Medical Research Council
guidelines and with the approval of the University of Syd-
ney Human Ethics Committee (approval number:2012/
043), as previously characterized and described (Slater
et al. 1994; Sivagurunathan et al. 2005; Brennan et al.
2009; Rybchyn et al. 2011). These cells express ALP,
osteocalcin, OPG, RANKL and sclerostin in cultures (Sla-
ter et al. 1994; Sivagurunathan et al. 2005; Brennan et al.
2009; Rybchyn et al. 2011). The study was conducted
using HOBs from several different donors. Each experi-
ment was conducted using HOBs from at least two differ-
ent donors. HOBs were routinely maintained in DMEM
containing 10% (v/v) FCS supplemented with
150 lmol L1 L-ascorbic acid 2-phosphate and b-glycero-
phosphate (10% DMEM). HOBs were seeded in 10%
DMEM at 1 9 104 cells per well and allowed to attach
overnight in 96 well plates for Cell Titer Blue, ALP, Cas-
pase-3 and BCA assays and at 1 9 106 cells per well in
six well plates for RNA extraction followed by PCR.
Table 1. Group characteristics.
Premenopause
(n = 8)
Postmenopause
(n = 10) P-value
Age (years) 36.1  2.7 62.8  2.6 <0.001
Height (cm) 162.7  1.8 161.2  1.6 0.54
Body mass (kg) 66.4  1.9 73.6  3.4 0.10
BMI (kg m2) 25.5  0.8 28.3  1.3 0.12
Glucose (mmol L1) 4.4  0.3 4.9  1.0 0.15
HbA1c (%) 5.3  1.0 5.5  1.0 0.16
VO2peak (mL kg
1
min1)
24.2  2.1 19.7  1.6 0.09
tOC (ng mL1) 19.8  2.0 28.2  2.0 0.01
UcOC (ng mL1) 9.9  1.0 13.9  1.4 0.04
P1NP (l L1) 43.4  4.4 67.2  7.6 0.02
b-CTX (l L1) 368.9  47.1 429.3  40.1 0.34
BMI, body mass index; HbA1c, glycosylated hemoglobin; tOC,
total osteocalcin; ucOC, undercarboxylated osteocalcin; P1NP, pro-
collagen type 1 N-terminal propeptide; b-CTx, b-isomerized C-
terminal telopeptides.
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HOBs were equilibrated in glucose-free, serum-free Marti-
nez buffer solution for 90 min prior to the addition of
media containing 0, 2.5, 5, 10, and 20 mmol L1 D-Glu-
cose with or without insulin (50 lU mL1, physiological
levels observed in postmenopausal women in this study
following OGTT) for 2 h, which was specifically chosen
to replicate the time frame of the OGTT performed in
this study in humans. All in vitro assays were performed
on three separate occasions, each in quintuplicates. Data
presented are combined from each assay.
Cell viability
Following treatment, HOB viability was assessed using
Cell Titer Blue (Promega, Wisconsin) performed accord-
ing to the manufacturer’s instructions.
Alkaline phosphatase (ALP) activity is used as a marker
of mature, bone-forming osteoblasts (Szulc and Delmas
2008). HOBs were lysed in PBS containing 0.1% (v/v)
TX-100 followed by the addition of p-Nitrophenyl Phos-
phate (p-NPP) to a final concentration of 1 mg mL1 in
0.1 mol L1 Glycine pH 95. The formation of the col-
ored product was monitored at 405 nm and the amount
(units; U) of ALP was interpreted from a standard curve
of recombinant ALP (Promega) incubated under the same
conditions.
Apoptosis was assessed by measuring activated caspase-
3 activity, using the fluorogenic Caspase-3 substrate Ac
(N-acetyle)-DEVD-AFC (7-amino-4-trifluoromethylcou-
marin) (Becton Dickinson, New Jersey) used according to
the manufacturer’s instructions. Data were corrected for
total cell protein using the bicinchoninic acid assay
(Pierce) on cells plated at the same density on the same
plate that had undergone the same treatment.
Osteocalcin and type 1 collagen RNA expression was
assessed by reverse transcription PCR. RNA was extracted
from HOBs plated in 6-well plates using a QIAGEN
RNeasy Mini extraction kit according to the manufac-
turer’s instructions. Total RNA (2 lg) was converted to
cDNA using the Bioline SensiFASTTM cDNA Synthesis kit.
PCR was performed using the
iTaqTM Universal SYBR Green Supermix kit according
to manufacturer’s instructions and the following primers
designed specifically for this study: osteocalcin Fwd:50A
TGAGAGCCCTCACACTCCTC and Rev:50CGGGCCGTA-
GAAGCGCCGAT, and col1a1 Fwd:50CTGACCTTCCTG
CGCCTGAT and Rev: 50 GTCTGGGGCACCAACGTCCA.
Human b2-microglubulin (hB2M) was used to normalize
the expression of osteocalcin and collagen. hB2M primers
were as follows: Fwd:50GCCTTAGCTGTGCTCGCGCT
and Rev: 50ACCTGAATCTTTGGAGTACGCT. 5 mmol
L1 glucose-treated cells was chosen as the calibrator
sample.
Statistical analyses
A repeated-measures analysis of variance (ANOVA) with
a post hoc analysis, LSD correction, was used to identify
differences between time points in the in vivo study. Dif-
ferences between glucose concentrations in the in vitro
study were analyzed with a multivariate analysis with LSD
correction. In addition, differences between glucose alone
and glucose plus insulin for each pair HOBs at a specific
glucose concentration were analyzed with paired t test.
Multilinear regression model with age, BMI, serum glu-
cose, and insulin levels following resting and exercise
OGTTs were used to determine association with BRMs.
All data are reported as mean  standard error of mean
(SEM) and all statistical analyses were conducted at the
95% level of significance (P ≤ 0.05).
Results
In vivo
Glucose and insulin levels following resting and
exercise OGTTs
Serum glucose returned to baseline in pre and post-
menopausal women 2 h following the OGTT at rest
(Fig. 1A and B). Serum glucose was 20–25% higher after
the exercise OGTT compared with the resting OGTT
(P < 0.05; Fig. 1A and B). Exercise had no effect on
serum insulin in pre or postmenopausal women (Fig. 1C
and D). However, serum insulin was elevated four to six-
fold (P < 0.05) in both groups after OGTT in resting and
exercise experiments (Fig. 1C and D).
Bone remodeling markers and ucOC levels
following exercise and glucose-load
In the resting trial, glucose-load suppressed P1NP (10–
13%, P < 0.05) and b-CTX by two-fourfold (P < 0.001)
in pre (Fig. 2A and C) and postmenopausal women
(Fig. 2B and D). Exercise OGTT had no effect on P1NP
and b-CTX in either population (Fig. 2A–D). Similar to
the resting trial, both markers were suppressed two hours
post glucose load that commenced after exercise in pre
and postmenopausal women (P < 0.01, Fig. 2A–D).
Figure 3 shows the effects of glucose-load and exercise
on tOC and ucOC. In the resting trial, tOC was sup-
pressed 2 h post-OGTT in pre (~12%, P = 0.001, Fig. 3A)
and postmenopausal women (~13%, P = 0.001, Fig. 3B).
Compared to baseline levels, ucOC was suppressed, but
not statistically so, following resting OGTT in pre-
menopausal women (8%, P = 0.16, Fig. 3C) and in
postmenopausal women (~12%, P = 0.03, Fig. 3D).
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Exercise had no effect on tOC in pre or post-
menopausal women (Fig. 3A and B). In contrast, exercise
increased ucOC in pre (~14%, P = 0.039, Fig. 3C) and
postmenopausal women (~9%, P = 0.008, Fig. 3D).
In postmenopausal women, tOC and ucOC were sup-
pressed 2 h after the exercise OGTT (8–20%, P < 0.05),
with no differences between the resting trial and the exer-
cise trial (Fig. 3A–D). In premenopausal women, ucOC
was not affected, compared to baseline by the glucose
load at rest (P = 0.16) or following exercise (P = 0.46,
Fig. 3C).
The associations between glucose levels and BRMs were
studied with a multivariable analysis. A higher baseline
serum glucose was associated with a lower P1NP
(b = 0.76, P = 0.009), ucOC (b = 0.58, P = 0.039)
and tOC (b = 0.51, P = 0.10). Insulin was positively
associated with P1NP ((b = 0.92, P = 0.002), tOC
(b = 0.72, P = 0.027) and ucOC (b = 0.97, P = 0.002).
Serum glucose or insulin were not correlated with b-CTX
at baseline, but a higher serum glucose post-OGTT at rest
was associated with lower b-CTX levels (b = 0.65,
P = 0.046).
In addition, a higher change in serum glucose following
resting OGTT, but not age, BMI or the change in serum
insulin, was correlated with greater reduction in bone for-
mation (P1NP, b = 0.70, P = 0.012 and tOC,
b = 0.44, P = 0.15). The change in the BRMs following
OGTT that commenced postexercise did not correlate
with the change in either glucose or insulin.
In vitro
Assays of cultured human osteoblasts (HOBs)
treated for 2 h with D-glucose
Cell viability
Glucose (10 and 20 mmol L1) without insulin treatment,
reduced cell viability compared with 2.5 and 5 mmol L1
(20–40%, P < 0.05). No glucose (0 mmol L1) reduced
cell viability compared with 2.5 and 5 mmol L1. Insulin
treatment increased HOBs viability in all D-glucose con-
centrations by 25–60% (P < 0.05, Fig. 4A).
Apoptosis
Caspase 3 activity was lowest at 2.5 and 5 mmol L1
(Fig. 4B). Apoptosis of HOBs was highest at 0, 10 and
20 mmol L1 D-glucose (P < 0.05 compared with 2.5
A
C D
B
Figure 1. The effects of glucose load and acute exercise on serum glucose and insulin levels in pre (A and C) and post (B and D)menopausal
women. *indicates P < 0.05
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AC D
B
Figure 2. The effects of glucose load and acute exercise on serum P1NP and b-CTX in pre (A and C) and post (B and D)-menopausal women.
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
A B
C D
Figure 3. The effects of glucose-load and acute exercise on serum tOC (total osteocalcin) and ucOC (undercarboxylated osteocalcin) in pre (A
and C) and post (B and D)- menopausal women. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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and 5 mmol L1; Fig. 4B). However, insulin treatment
prevented apoptosis at 10 and 20 mmol L1 and in the
absence of glucose (P < 0.05, Fig. 4B).
Alkaline phosphatase
ALP activity increased by twofold (P < 0.05) from 0 and
2.5 mmol L1 to 5 mmol L1 D-glucose (Fig. 4C). ALP
was lower in high glucose concentrations (10 mmol L1,
P = 0.06 and 20 mmol L1, P = 0.02 mmol L1) com-
pared with 5 mmol L1 (Fig. 4C). Insulin increase ALP
activity at 20 mmol L1 glucose concentrations but not
significantly (P = 0.11, Fig. 4C).
Osteocalcin
RNA expression was highest at 5 mmol L1 glucose alone
compared to all other concentrations (P < 0.05). The
addition of insulin resulted in no change across the glu-
cose concentrations (Fig. 4D).
Type 1 collagen
Col1a1 expression was significantly higher at 5 mmol L1
glucose with and without insulin compared to other
lower and higher concentrations, however, compared to
the expression of other osteoblast markers; this expression
seemed relatively stable across all concentrations during
this time period.
Discussion
We have reported, and now confirm, that BRMs are sup-
pressed after a glucose-load and that higher fasting serum
glucose is associated with lower BRMs (Clowes et al.
2002; Iglesias et al. 2011; Schwetz et al. 2014). Glucose-
loading also decreased ucOC in postmenopausal women.
Acute exercise did not offset the suppressive effect of the
glucose-load on BRMs. Exposure to high glucose in vitro
increased osteoblast apoptosis, reduced osteoblast life
span and ALP and osteocalcin expression. Exposure to
insulin rescued these deleterious effects on osteoblasts.
A B
C D
E
Figure 4. Cell viability (panel A), apoptosis (panel B) ALP and OC activity (panels C and D respectively) and collagen expression (panel E) of
cultured human osteoblasts (HOBs) treated with increasing concentrations of D-glucose. Solid black lines: glucose alone; Dashed lines: glucose
plus insulin (50uU mL1). *P < 0.05 compared to 5 mmol 1, **P < 0.01 compared to 5 mmol 1, #P < 0.05 compared to 2.5, ##P < 0.01
compared to 2.5, φP < 0.05 compared to 10 mmol L1, dP < 0.05 compared to 0, $P = 0.051 between 20 mmol L1 and 5 mmol L1. &
P < 0.05 between groups, € p < 0.01 between groups.
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Acute high levels of glucose reduce remodeling rate
in vivo and osteoblast viability in vitro. It was previously
reported that high glucose reduces ALP expression by
50% in osteoblasts and that insulin treatment prevented
this effect (Cunha et al. 2014). We extend these observa-
tions by demonstrating that high concentrations of glu-
cose suppressed ALP activity and osteocalcin expression
in osteoblasts, increased osteoblast apoptosis and so
reduced osteoblast survival in vitro; high concentrations
of glucose also led to increased Caspase 3 activity, an
early marker of apoptotic pathway activation. In addition,
these supraphysiological levels of glucose reduced osteo-
blast viability quantified as the activity of the electron
transport chain and the gene expression of markers of
bone formation, osteocalcin and type 1 collagen, although
the latter was subtle (but significant). While cell culture
media often contains high glucose concentrations, we
show here that osteoblasts may perform functionally bet-
ter in more physiological concentrations of glucose. The
effects of glucose were not due to osmotic changes as the
same concentrations of D-mannitol had no effect on
osteoblasts (data not shown). Importantly, we report that
insulin treatment rescued these deleterious effects on
osteoblasts in vitro. This in vitro finding is aligned with
our in vivo data where higher serum glucose was associ-
ated with lower BRMs while higher insulin was associated
with higher markers of bone formation and ucOC and a
higher serum glucose levels was correlated with a lower
b-CTX postresting OGTT.
Thus, long-term exposure to high glucose levels in
patients with T2DM may lead to low bone remodeling
which may actually slow bone loss and structural deterio-
ration. However, the less remodeled bone has more time
to undergo collagen cross-linking and more complete sec-
ondary mineralization which may compromise these bone
‘qualities’. This may explain the well documented higher
risk for fracture despite preservation or increase in BMD
in patients with type 2 diabetes (Schwartz et al. 2011; Les-
lie et al. 2012; Patsch et al. 2013).
Following OGTT, with and without exercise, glucose-
loading suppressed BRMs in both groups and ucOC in
postmenopausal women. This inability of moderate inten-
sity exercise to prevent the suppressive effect of glucose is
not understood, especially considering the high insulin
levels observed post-OGTT following exercise. However,
we also observed higher serum glucose levels after the pos-
texercise OGTT (not the resting OGTT) which may inter-
fere with osteoblast function. Nevertheless, our results raise
the possibility that the crosstalk between ucOC and glucose
metabolism is bidirectional. Conceivably, the low circulat-
ing levels of ucOC reported in patients with T2DM as the
trigger for higher glucose levels are in fact themselves a
result of high circulating levels of glucose. This finding
may indicate a feedback loop that regulates both glucose
and ucOC as we propose in Figure 5.
The study had several limitations. The sample size was
small in the in vivo study. Nevertheless, we did detect
suppressive effects of glucose on BRMs in pre and post-
menopausal women, but we may have been unable to
detect associations between ucOC and BRMs in pre-
menopausal women. The long-term effects of high glucose
levels on bone microarchitecture were not examined. In
addition, this study focuses on osteoblasts survival and
functions. It is possible that high glucose levels may also
have an effect on osteoclasts survival and functions, but
this was not assessed in this study and as such future
studies should examine the effects of high glucose on
these cells. Further work is needed to determine whether
exercise failed to modify the suppressive effect of glucose
because of the detrimental effect of glucose on osteoblast
survival and function.
In conclusion, BRMs and ucOC in women are sup-
pressed after a glucose-load and acute exercise did not
offset the suppressive effect of the glucose-load on BRMs.
This may be, in part, due to increased osteoblast apopto-
sis, reduced osteoblast life span and ALP activity as well
as osteocalcin and collagen RNA expression. Exposure to
insulin rescued these deleterious effects on osteoblasts.
Insulin  sensitivity
Blood glucose
Osteoblast 
bone formation
Microstructural 
deterioraon 
Remodelling
markers and rate 
ucOC
Remodelling
balance 
Ageing and T2DM
Bone Qualies 
Fracture risk
Figure 5. Ageing and T2DM are associated with reduced insulin
sensitivity and increased blood glucose concentration which may
reduce osteoblast bone formation, remodeling rate and circulating
ucOC (undercarboxylated osteocalcin). The reduced ucOC reduces
insulin sensitivity. The reduced remodeling rate compromises bone’s
qualities but slows microstructural deterioration. The reduced
osteoblast mediated bone formation reduces remodeling balance
increasing microstructural deterioration. The net effect on bone’s
microstructure and qualities establishes fracture risk.
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Future studies should explore whether circulating glucose
may be an independent determinant of bone formation at
the cellular (BMU) level, and the rate of bone remodeling
– the numbers of BMUs remodeling bone at any one
time. If so, it is likely to be a net deleterious effect as the
reduced volume of bone deposited produces microstruc-
tural deterioration while reduced remodeling rate com-
promises bone matrix composition.
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